We would like to thank Misko and Rawlins for their interest in our recent article. We acknowledge and agree with their concerns regarding the lack of uniform information available to community pharmacists and other health practitioners regarding the use of doxylamine in pregnancy. Unfortunately, this situation is not unique to doxylamine and is reflective of a larger problem regarding medicines labelling in pregnancy. At this point in time, there is no requirement for medication packaging and consumer medicines information to include evidence-based information on use in pregnancy, such that consumers and providers are able to rationally weigh up risks and benefits. This often leads to unnecessary confusion and anxiety regarding medication use in pregnancy...
|Number of pages||1|
|Journal||Australian and New Zealand Journal of Obstetrics and Gynaecology|
|Publication status||Published - Dec 2021|
- Medication use in pregnancy